Long-term results of medical treatment in benign prostatic hyperplasia

• Published in: Urology (Ridgewood, N.J.) Vol. 68; no. 5; pp. 1015 - 1019
• Main Authors: Kim, Chun Il, Chang, Hyuk Soo, Kim, Byoung Kun, Park, Choal Hee
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.11.2006; Elsevier Science
• Subjects: Acute Disease; Adrenergic alpha-Antagonists - therapeutic use; Aged; Biological and medical sciences; Cholestenone 5 alpha-Reductase - antagonists & inhibitors; Drug Therapy, Combination; Gynecology. Andrology. Obstetrics; Humans; Incidence; Male; Male genital diseases; Medical sciences; Nephrology. Urinary tract diseases; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - drug therapy; Prostatic Hyperplasia - surgery; Retrospective Studies; Time Factors; Tumors; Tumors of the urinary system; Urinary Retention - epidemiology; Urinary Retention - etiology; Urinary Retention - surgery; Urinary tract. Prostate gland; Medicine; Nephrology; Urinary system disease; Treatment; Prostate disease; Benign prostatic hyperplasia; Benign neoplasm; Male genital diseases; Long term; Urology
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2006.06.003

In real-life clinical practice, we determined the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH)-related surgery in patients with BPH who received alpha-adrenergic receptor blocker (α-blocker) and/or 5-alpha-reductase inhibitor combination treatment. This retrospective study enrolled 341 patients with BPH who were prescribed an α-blocker and/or a 5-alpha-reductase inhibitor as their first treatment from January 1997 to June 1999. Using follow-up data from a 6 to 8-year period, we calculated the incidence of AUR and BPH-related surgery in the α-blocker-only group and in the combination group. Of the 341 patients, 192 were in the α-blocker group and 149 were in the combination group. Of these, 17.7% in the α-blocker group and 12.1% in the combination group experienced AUR ( P <0.05). BPH-related surgery was performed in 10.9% of the α-blocker-only group and 6.0% of the combination group ( P <0.05). The incidence of AUR and BPH-related surgery was reduced by 32.3% and 48.9% when the prostate volume was larger than 35 g and by 49.4% and 60.6% when the prostate-specific antigen level was greater than 2.0 ng/mL, respectively, in the combination group compared with the corresponding values in the α-blocker group. Real-life clinical practice showed that long-term combination treatment with α-blockers and 5-alpha-reductase inhibitors reduced the risk of BPH progression, such as AUR or BPH-related surgery, compared with α-blocker-only treatment.